INS and metabolic dysfunction-associated steatohepatitis: These treatments have diverse pharmacological activities such as improvement of insulin sensitivity, stimulation of lipid oxidation, as well as reduction of de novo lipogenesis, oxidative stress, and inflammation that are characteristics of NASH [17].